The Patient-Oriented Eczema Measure
2004/12/01 by Carolyn R. Charman, Carolyn Charman, Andrea J. Venn +3 · 28 citations
Medicine · #Dermatology and Skin Diseases #Allergic Rhinitis and Sensitization #Asthma and respiratory diseases
paper · doi:10.1001/archderm.140.12.1513
Abstract
OBJECTIVE: To develop a simple, valid, repeatable, and readily understandable patient-oriented assessment measure for monitoring disease activity in children and adults with atopic eczema. DESIGN: Qualitative semistructured patient interviews identified a list of symptoms of atopic eczema. These symptoms were quantitatively analyzed in a larger patient population to identify which symptoms were important to patients and amenable to monitoring as part of a scoring system. SETTING: The outpatient Department of Dermatology at the Queen's Medical Centre, University Hospital, Nottingham, England, and 5 local general practices. PATIENTS: Four hundred thirty-five patients with atopic eczema. RESULTS: Seven symptoms were incorporated into the final patient-oriented eczema measure using a simple 5-point scale of frequency of occurrence during the previous week, with a maximum total score of 28. Validity testing against the Dermatology Life Quality Index, Children's Dermatology Life Quality Index, and patients' global severity assessments showed good correlation (r = 0.78, r = 0.73, and r = 0.81, respectively; P<.001). Internal consistency was high (Cronbach alpha = 0.88), and test-retest reliability was good, with 95% of scores falling within 2.6 points on repeat testing (mean score difference, 0.04; SD, 1.32). Individual variables in the measure demonstrated sensitivity to change during a 4-week in-clinic period and an 18-week randomized controlled clinical trial. CONCLUSION: The patient-oriented eczema measure is a practical self-assessed measurement tool for monitoring aspects of atopic eczema that are important to patients in routine clinical practice or in the clinical trial setting.
Cited by
- Three‐Year Follow‐Up of the PACI Randomized Controlled Trial (PACI‐ON): Effects of Early Intervention for Atopic Dermatitis on Atopic March
- Itching in Atopic Dermatitis: Patient- and Physician-reported Outcomes in the German Atopic Dermatitis Registry TREATgermany
- Nocturnal Scratching and Quality of Sleep in Children with Atopic Dermatitis
- Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. [europepmc]
- Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force. [europepmc]
- Emollients and moisturisers for eczema. [europepmc]
- Discordance Between Physician- and Patient-Reported Disease Severity in Adults with Atopic Dermatitis: A US Cross-Sectional Survey. [europepmc]
- Targeted anti-staphylococcal therapy with endolysins in atopic dermatitis and the effect on steroid use, disease severity and the microbiome: study protocol for a randomized controlled trial (MAAS trial). [europepmc]
- Severity strata for five patient-reported outcomes in adults with atopic dermatitis. [europepmc]
- Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness. [europepmc]
- Measurement properties of three assessments of burden used in atopic dermatitis in adults. [europepmc]
- Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Hand Eczema in Adults. [europepmc]
- Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis. [europepmc]
- Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection. [europepmc]
- The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. [europepmc]
- Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. [europepmc]
- Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP). [europepmc]
- Study protocol for the Melbourne Infant Study: BCG for Allergy and Infection Reduction (MIS BAIR), a randomised controlled trial to determine the non-specific effects of neonatal BCG vaccination in a low-mortality setting. [europepmc]
- Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1). [europepmc]
- Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. [europepmc]
- Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. [europepmc]
- Skin care interventions in infants for preventing eczema and food allergy. [europepmc]
- Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. [europepmc]
- Internet-Delivered Cognitive Behavior Therapy for Atopic Dermatitis: A Randomized Clinical Trial. [europepmc]
- Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial. [europepmc]
- Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. [europepmc]
- Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting. [europepmc]
- Eczema Care Online behavioural interventions to support self-care for children and young people: two independent, pragmatic, randomised controlled trials. [europepmc]
Related